Olema Pharmaceuticals, Inc. – NASDAQ:OLMA
Olema Pharmaceuticals stock price today
$5.51
-0.64
-10.41%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 9 hours
Olema Pharmaceuticals stock price monthly change
-50.00%
month
Olema Pharmaceuticals stock price quarterly change
-50.00%
quarter
Olema Pharmaceuticals stock price yearly change
-57.73%
year
Olema Pharmaceuticals key metrics
Market Cap | 354.67M |
Enterprise value | 110.84M |
P/E | -1.34 |
EV/Sales | N/A |
EV/EBITDA | -1.06 |
Price/Sales | N/A |
Price/Book | 0.66 |
PEG ratio | 0.02 |
EPS | -2.02 |
Revenue | N/A |
EBITDA | -109.33M |
Income | -99.33M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeOlema Pharmaceuticals stock price history
Olema Pharmaceuticals stock forecast
Olema Pharmaceuticals financial statements
Average Price Target
$27
Potential upside: 390.01%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 0 | -20.09M | |
|---|---|---|---|
| Sep 2023 | 0 | -21.50M | |
| Dec 2023 | 1.88M | -26.77M | -1421.02% |
| Mar 2024 | 0 | -30.97M |
| Jun 2023 | 177624000 | 16.04M | 9.03% |
|---|---|---|---|
| Sep 2023 | 292799000 | 17.66M | 6.03% |
| Dec 2023 | 276945000 | 23.05M | 8.32% |
| Mar 2024 | 263694000 | 27.37M | 10.38% |
| Jun 2023 | -22.11M | 14.11M | 2.04M |
|---|---|---|---|
| Sep 2023 | -22.74M | -25.43M | 130.62M |
| Dec 2023 | -18.47M | -30.91M | 523K |
| Mar 2024 | -23.49M | -20.14M | 8.82M |
Olema Pharmaceuticals alternative data
| Aug 2023 | 62 |
|---|---|
| Sep 2023 | 67 |
| Oct 2023 | 67 |
| Nov 2023 | 67 |
| Dec 2023 | 70 |
| Jan 2024 | 70 |
| Feb 2024 | 70 |
| Mar 2024 | 74 |
| Apr 2024 | 74 |
| May 2024 | 74 |
| Jun 2024 | 75 |
| Jul 2024 | 75 |
Olema Pharmaceuticals other data
14.41%
-68.67%
of OLMA is owned by hedge funds
29
-35
5.76M
-27.49M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 0 | 25000 |
| Feb 2024 | 0 | 30000 |
| Mar 2024 | 0 | 20000 |
| Apr 2024 | 0 | 15000 |
| May 2024 | 0 | 20000 |
| Jun 2024 | 0 | 1205000 |
| Jul 2024 | 0 | 10000 |
| Aug 2024 | 0 | 2400000 |
| Dec 2024 | 700761 | 894978 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | GRAHAM G. WALMSLEY director | Common Stock | 700,761 | $6.75 | $4,730,137 | ||
Sale | GRAHAM G. WALMSLEY director | Common Stock | 700,761 | $6.75 | $4,730,137 | ||
Option | ZOJWALLA NASEEM officer: CHIEF MEDICAL OFFICER | Common Stock | 14,000 | $4.87 | $68,180 | ||
Option | ZOJWALLA NASEEM officer: CHIEF MEDICAL OFFICER | Stock Option (Right to Buy) | 14,000 | $4.87 | $68,180 | ||
Sale | KOVACS SHANE WILLIAM CHARLES officer: CH. OPERATING & FINANC.. | Common Stock | 17,950 | $8.66 | $155,447 | ||
Sale | KOVACS SHANE WILLIAM CHARLES officer: CH. OPERATING & FINANC.. | Common Stock | 406 | $9.39 | $3,812 | ||
Sale | BOHEN SEAN director, officer.. | Common Stock | 55,907 | $8.66 | $484,155 | ||
Sale | BOHEN SEAN director, officer.. | Common Stock | 1,267 | $9.39 | $11,897 | ||
Sale | HARMON CYRUS director | Common Stock | 7,958 | $8.66 | $68,916 | ||
Sale | HARMON CYRUS director | Common Stock | 179 | $9.39 | $1,681 |
| Patent |
|---|
Application Filling date: 6 Jul 2020 Issue date: 25 Aug 2022 |
Grant Filling date: 17 Apr 2020 Issue date: 25 Jan 2022 |
Application Filling date: 17 Apr 2020 Issue date: 4 Mar 2021 |
Grant Filling date: 23 Apr 2019 Issue date: 21 Apr 2020 |
Application Filling date: 23 Apr 2019 Issue date: 15 Aug 2019 |
-
What's the price of Olema Pharmaceuticals stock today?
One share of Olema Pharmaceuticals stock can currently be purchased for approximately $5.51.
-
When is Olema Pharmaceuticals's next earnings date?
Unfortunately, Olema Pharmaceuticals's (OLMA) next earnings date is currently unknown.
-
Does Olema Pharmaceuticals pay dividends?
No, Olema Pharmaceuticals does not pay dividends.
-
How much money does Olema Pharmaceuticals make?
Olema Pharmaceuticals has a market capitalization of 354.67M.
-
What is Olema Pharmaceuticals's stock symbol?
Olema Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "OLMA".
-
What is Olema Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Olema Pharmaceuticals?
Shares of Olema Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Olema Pharmaceuticals's key executives?
Olema Pharmaceuticals's management team includes the following people:
- Dr. Cyrus L. Harmon Ph.D. Chief Technology Officer & Director(age: 54, pay: $657,990)
- Dr. Sean P. Bohen Pres, Chief Executive Officer & Director(age: 58, pay: $643,090)
- Mr. John B. Moriarty Jr. Executive Vice President, Chief Legal Officer & Corporation Sec.(age: 57, pay: $434,320)
- Dr. Peter J. Kushner Ph.D. Chief Scientific Officer(age: 86, pay: $429,950)
-
How many employees does Olema Pharmaceuticals have?
As Jul 2024, Olema Pharmaceuticals employs 75 workers, which is 1% more then previous quarter.
-
When Olema Pharmaceuticals went public?
Olema Pharmaceuticals, Inc. is publicly traded company for more then 4 years since IPO on 19 Nov 2020.
-
What is Olema Pharmaceuticals's official website?
The official website for Olema Pharmaceuticals is olema.com.
-
Where are Olema Pharmaceuticals's headquarters?
Olema Pharmaceuticals is headquartered at 512 2nd Street, San Francisco, CA.
-
How can i contact Olema Pharmaceuticals?
Olema Pharmaceuticals's mailing address is 512 2nd Street, San Francisco, CA and company can be reached via phone at +65 02435555.
-
What is Olema Pharmaceuticals stock forecast & price target?
Based on 1 Wall Street analysts` predicted price targets for Olema Pharmaceuticals in the last 12 months, the avarage price target is $27. The average price target represents a 390.01% change from the last price of $5.51.
Olema Pharmaceuticals company profile:
Olema Pharmaceuticals, Inc.
olema.comExchange:
NASDAQ
Full time employees:
74
Industry:
Biotechnology
Sector:
Healthcare
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
512 2nd Street
San Francisco, CA 94107
San Francisco, CA 94107
CIK: 0001750284
ISIN: US68062P1066
CUSIP: 68062P106
